Need help choosing the right code?
Ask CasePilot about procedures, modifiers, bundling, and coding guidance.
Try CasePilot© Copyright 2026 American Medical Association. All rights reserved.
The CPT® Code 81521 pertains to a specific molecular genomic testing procedure used in oncology, particularly for breast cancer. This test involves mRNA microarray gene expression profiling, which assesses the expression levels of 70 content genes, also referred to as signature genes, alongside 465 housekeeping genes. The tissue samples utilized for this analysis can be either fresh frozen or formalin-fixed paraffin-embedded breast tumor tissue. The primary purpose of this test is to provide a prognostic indicator regarding the risk of distant metastasis, which is the spread of cancer from the primary site to other parts of the body. The results of this test are reported as an index that correlates with the risk of recurrence-free survival over a five-year period. This is particularly relevant for women diagnosed with Stage I or II invasive breast cancer, regardless of hormone receptor status, and with tumor sizes less than 5 cm. The process involves a pathologist examining histology slides to identify and mark tumor cells, followed by a technician isolating the mRNA from these cells. The extracted mRNA is then analyzed using a specialized computer program to generate a risk of recurrence (ROR) score. This score, in conjunction with clinical data such as cancer type, tumor size, and hormone receptor status, helps categorize the risk of recurrence into low or high categories, providing critical information for treatment planning and patient management.
© Copyright 2026 Coding Ahead. All rights reserved.
The procedure associated with CPT® Code 81521 is indicated for the assessment of breast cancer patients, specifically for those diagnosed with Stage I or II invasive disease. The following conditions and characteristics warrant the use of this molecular genomic test:
The procedure for CPT® Code 81521 involves several critical steps to ensure accurate gene expression profiling. Each step is detailed as follows:
After the completion of the molecular genomic testing, the results are compiled and reported as an index related to the risk of distant metastasis. The ROR score provides critical prognostic information, indicating the probability of tumor recurrence within five years without adjuvant treatment such as chemotherapy or hormone therapy. A low risk score (0.0 to +1.0) suggests a 10% probability of recurrence, while a high risk score (-1.0 to 0.0) indicates a 29% probability of recurrence. This information is essential for oncologists and healthcare providers in making informed decisions regarding patient management and treatment options. Follow-up care may include discussions about the implications of the test results and potential treatment strategies based on the risk assessment.
| Short Descr | ONC BREAST MRNA 70 GENES | Medium Descr | ONC BREAST MRNA MICRORA GENE XPRSN PRFL 70 GENES | Long Descr | Oncology (breast), mRNA, microarray gene expression profiling of 70 content genes and 465 housekeeping genes, utilizing fresh frozen or formalin-fixed paraffin-embedded tissue, algorithm reported as index related to risk of distant metastasis | Status Code | Statutory Exclusion (from MPFS, may be paid under other methodologies) | Global Days | XXX - Global Concept Does Not Apply | PC/TC Indicator (26, TC) | 9 - Not Applicable | Multiple Procedures (51) | 9 - Concept does not apply. | Bilateral Surgery (50) | 9 - Concept does not apply. | Physician Supervisions | 09 - Concept does not apply. | Assistant Surgeon (80, 82) | 9 - Concept does not apply. | Co-Surgeons (62) | 9 - Concept does not apply. | Team Surgery (66) | 9 - Concept does not apply. | Diagnostic Imaging Family | 99 - Concept Does Not Apply | CLIA Waived (QW) | No | APC Status Indicator | Service Paid under Fee Schedule or Payment System other than OPPS | Type of Service (TOS) | 5 - Diagnostic Laboratory | Berenson-Eggers TOS (BETOS) | none | MUE | 1 |
| 59 | Distinct procedural service: under certain circumstances, it may be necessary to indicate that a procedure or service was distinct or independent from other non-e/m services performed on the same day. modifier 59 is used to identify procedures/services, other than e/m services, that are not normally reported together, but are appropriate under the circumstances. documentation must support a different session, different procedure or surgery, different site or organ system, separate incision/excision, separate lesion, or separate injury (or area of injury in extensive injuries) not ordinarily encountered or performed on the same day by the same individual. however, when another already established modifier is appropriate it should be used rather than modifier 59. only if no more descriptive modifier is available, and the use of modifier 59 best explains the circumstances, should modifier 59 be used. note: modifier 59 should not be appended to an e/m service. to report a separate and distinct e/m service with a non-e/m service performed on the same date, see modifier 25. | 90 | Reference (outside) laboratory: when laboratory procedures are performed by a party other than the treating or reporting physician or other qualified health care professional, the procedure may be identified by adding modifier 90 to the usual procedure number. | CC | Procedure code change (use 'cc' when the procedure code submitted was changed either for administrative reasons or because an incorrect code was filed) | GZ | Item or service expected to be denied as not reasonable and necessary |
|
Date
|
Action
|
Notes
|
|---|---|---|
| 2018-01-01 | Added | Code Added. |
Get instant expert-level medical coding assistance.